Scarica l'app Stockscreener
17.22
3.10%
-0.55
Dopo l'orario di chiusura:
17.71
0.49
+2.85%
Precedente Chiudi:
$17.77
Aprire:
$17.9
Volume 24 ore:
129.24K
Relative Volume:
0.49
Capitalizzazione di mercato:
$781.32M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+9.68%
1M Prestazione:
-9.70%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$17.02
$17.98
Intervallo di 1 settimana:
$16.04
$18.50
Portata 52W:
$12.24
$21.55
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Nome
Maplight Therapeutics Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare MPLT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
17.22 | 806.28M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-21 | Iniziato | Jefferies | Buy |
| 2025-11-21 | Iniziato | Leerink Partners | Outperform |
| 2025-11-21 | Iniziato | Morgan Stanley | Overweight |
| 2025-11-21 | Iniziato | Stifel | Buy |
Maplight Therapeutics Inc Borsa (MPLT) Ultime notizie
Capital Markets Group Of The Year: Cooley - Law360
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down – Time to Sell? - Defense World
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Average Price Target from Brokerages - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap DownTime to Sell? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Malenka sells MapLight (MPLT) shares worth $126,860 By Investing.com - Investing.com Canada
Malenka sells MapLight (MPLT) shares worth $126,860 - Investing.com
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 7,039 Shares of Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $121,672.60 in Stock - Defense World
Malenka sells MapLight Therapeutics (MPLT) stock worth $635,857 By Investing.com - Investing.com Nigeria
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 6,524 Shares of Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 21,262 Shares - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Sells $119,743.32 in Stock - MarketBeat
Malenka sells MapLight Therapeutics (MPLT) stock worth $635,857 - Investing.com
Maplight Therapeutics (NASDAQ:MPLT) Shares Up 4.8% – Here’s Why - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 4.8%Still a Buy? - MarketBeat
Biopharma financings pick up in Q4 to cap uneven 2025 recovery - BioWorld MedTech
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7.7%Here's Why - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 10.5%Time to Buy? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap UpHere's What Happened - MarketBeat
MapLight Therapeutics stock rises after accelerating clinical trial timelines By Investing.com - Investing.com Nigeria
MapLight Therapeutics stock rises after accelerating clinical trial timelines - Investing.com
MapLight Therapeutics accelerates timeline for Phase 2 trial results By Investing.com - Investing.com Nigeria
MapLight updates trial timelines and highlights CNS pipeline - TipRanks
MapLight Therapeutics accelerates timeline for Phase 2 trial results - Investing.com
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 - The Manila Times
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 - GlobeNewswire Inc.
MapLight Therapeutics Expects Topline Results From Phase 2 Zephyr, Iris Trials in Q3 - marketscreener.com
FDA grants fast track designation to MapLight’s Alzheimer’s drug By Investing.com - Investing.com Nigeria
Maplight Therapeutics (MPLT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
MapLight Therapeutics' Alzheimer's Psychosis Drug Granted FDA Fast Track Status - Nasdaq
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis - The Manila Times
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 7.9%Should You Sell? - MarketBeat
MapLight’s phase 2 Alzheimer’s psychosis trial marks a key milestone for MPLT investors - MSN
What is the current Price Target and Forecast for MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight’s Phase 2 Alzheimer’s Psychosis Trial Marks a Key Milestone for MPLT Investors - TipRanks
MapLight Therapeutics Earnings Notes - Trefis
MapLight Therapeutics advances CNS drug pipeline - MSN
MapLight’s ML-004 Autism Extension Study: What Ongoing Safety Data Mean for Investors - TipRanks
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P TMI Index - marketscreener.com
Aktis Oncology files for US IPO as biotech listings rebound - whbl.com
Maplight Therapeutics (NASDAQ:MPLT) Upgraded by Wall Street Zen to Hold Rating - Defense World
MapLight2025 Funding Rounds & List of Investors - Tracxn
Maplight Therapeutics Inc Azioni (MPLT) Dati Finanziari
Non sono disponibili dati finanziari per Maplight Therapeutics Inc (MPLT). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):